Stock chart
Analyses on Wilk (3)
- March 30, 2026March 30, 2026
- Follow-up
Wilk: The Bridge Route, From Cosmetics and Yogurt to the Question of What Counts as Real Commercialization
Wilk moved closer to market through a bridge route built around biomimicry, cosmetics, and yogurt, but the filing still does not show full commercialization proof for the cultured-milk core. It shows a chain of transition tests that remain dependent on regulation, partners, and…
- Follow-up
Wilk: How Much Runway Did the 2025 Raises and 2026 Rights Issue Really Buy
Wilk's 2025 financings and March 2026 rights issue mostly bought short runway on top of a burn rate that had already been sharply reduced by cuts, not a durable funding solution. By the report date, most of the 2025 financing had already been used, and the next layer again depen…
Wilk 2025: Cost Cutting Bought Time, but Commercial Proof Is Still Missing
Wilk finished 2025 with a much leaner operating base and a nearer commercialization route, but still without revenue and without enough funding cushion. The key question is no longer whether the technology is intriguing, but whether the cosmetics, biomimicry, and yogurt routes c…
